Unlocking the Therapeutic Potential of oxMIF

Targeting Disease at Its Source.

By harnessing the unique biology of oxidized Macrophage Migration Inhibitory Factor (oxMIF), ImmunoOne provides access to differentiated scientific expertise, therapeutic assets, and partnering opportunities across inflammation and cancer. Built on more than two decades of pioneering oxMIF research and antibody engineering expertise, ImmunoOne is the gateway to a disease-restricted target with broad therapeutic and commercial potential

A Disease-Restricted Target for Precision Therapeutics

oxMIF is selectively present at sites of inflammation and cancer, but absent from healthy tissue. This enables highly selective therapeutic intervention precisely where it matters most.

A Disease-Restricted Target for Precision Therapeutics

oxMIF is selectively present at sites of inflammation and cancer, but absent from healthy tissue. This enables highly selective therapeutic intervention precisely where it matters most.

Therapeutic Areas.

Oncology

Cancer remains a leading cause of death worldwide, accounting for nearly one in six deaths globally. Despite significant treatment advances, substantial unmet needs persist across solid tumors. By targeting oxMIF — a disease-associated conformer of MIF that arises within the oxidative tumor microenvironment — ImmunoOne's anti-oxMIF assets offer a differentiated approach to key mechanisms of tumor progression while sparing healthy tissue.

Chronic Inflammation

Chronic inflammatory diseases place a major and growing burden on patients and healthcare systems worldwide. oxMIF is generated under the oxidative conditions present at sites of active inflammation and acts as an upstream regulator of multiple inflammatory pathways. This provides a unique foundation for immunotherapeutic approaches that modulate disease-driving immune responses at their source, while preserving the physiological functions of native MIF.